Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma

Jae Cheol Jo, Dok Hyun Yoon, Shin Kim, Jung Sun Park, Chan Sik Park, Jooryung Huh, Sang Wook Lee, Jin Sook Ryu, Cheolwon Suh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background Radioimmunotherapy agents have a highly significant role in autologous stem cell transplantation as they improve tolerability and increase the efficacy of the conditioning regimen. Methods We retrospectively analyzed the efficacy and toxicity of yttrium-90 ibritumomab tiuxetan (Zevalin) combined with intravenous busulfan, cyclophosphamide, and etoposide (Z-BuCyE) compared with those of BuCyE alone followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). The efficacy, toxicity, and engraftment characteristics were compared between 19 patients who received Z-BuCyE and 19 historical controls who received BuCyE. Results The 2 treatment groups shared similar baseline characteristics. The median time to platelet engraftment (>20×10 9/L) and neutrophil engraftment (>0.5×10 9/L) did not significantly differ between the Z-BuCyE group (12 days and 10 days, respectively) and the BuCyE group (12 days and 10 days, respectively). No significant differences were observed between the groups with respect to toxicities and treatment-related mortality. The median follow-up period was 30.4 months, and median event-free survival was generally better in the Z-BuCyE group (12.5 months) vs. the BuCyE group (6.2 months, P=0.236). No significant difference in overall survival between the groups was noted. Conclusion Adding ibritumomab tiuxetan to BuCyE high-dose chemotherapy may benefit patients with relapsed or refractory B-cell NHL with no risk of additional toxicity.

Original languageEnglish (US)
Pages (from-to)119-125
Number of pages7
JournalKorean Journal of Hematology
Volume47
Issue number2
DOIs
StatePublished - Jun 1 2012

Fingerprint

Busulfan
Etoposide
Non-Hodgkin's Lymphoma
Cyclophosphamide
Stem Cell Transplantation
B-Cell Lymphoma
ibritumomab tiuxetan
Radioimmunotherapy
Disease-Free Survival
Neutrophils
Blood Platelets
Drug Therapy

Keywords

  • Autologous stem cell transplantation
  • Bucye
  • Non-hodgkin lymphoma
  • Yttrium-90 ibritumomab tiuxetan

Cite this

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma. / Jo, Jae Cheol; Yoon, Dok Hyun; Kim, Shin; Park, Jung Sun; Park, Chan Sik; Huh, Jooryung; Lee, Sang Wook; Ryu, Jin Sook; Suh, Cheolwon.

In: Korean Journal of Hematology, Vol. 47, No. 2, 01.06.2012, p. 119-125.

Research output: Contribution to journalArticle

Jo, Jae Cheol ; Yoon, Dok Hyun ; Kim, Shin ; Park, Jung Sun ; Park, Chan Sik ; Huh, Jooryung ; Lee, Sang Wook ; Ryu, Jin Sook ; Suh, Cheolwon. / Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma. In: Korean Journal of Hematology. 2012 ; Vol. 47, No. 2. pp. 119-125.
@article{dc3e202aef2945a28ec5d45ff8b5fb6c,
title = "Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma",
abstract = "Background Radioimmunotherapy agents have a highly significant role in autologous stem cell transplantation as they improve tolerability and increase the efficacy of the conditioning regimen. Methods We retrospectively analyzed the efficacy and toxicity of yttrium-90 ibritumomab tiuxetan (Zevalin) combined with intravenous busulfan, cyclophosphamide, and etoposide (Z-BuCyE) compared with those of BuCyE alone followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). The efficacy, toxicity, and engraftment characteristics were compared between 19 patients who received Z-BuCyE and 19 historical controls who received BuCyE. Results The 2 treatment groups shared similar baseline characteristics. The median time to platelet engraftment (>20×10 9/L) and neutrophil engraftment (>0.5×10 9/L) did not significantly differ between the Z-BuCyE group (12 days and 10 days, respectively) and the BuCyE group (12 days and 10 days, respectively). No significant differences were observed between the groups with respect to toxicities and treatment-related mortality. The median follow-up period was 30.4 months, and median event-free survival was generally better in the Z-BuCyE group (12.5 months) vs. the BuCyE group (6.2 months, P=0.236). No significant difference in overall survival between the groups was noted. Conclusion Adding ibritumomab tiuxetan to BuCyE high-dose chemotherapy may benefit patients with relapsed or refractory B-cell NHL with no risk of additional toxicity.",
keywords = "Autologous stem cell transplantation, Bucye, Non-hodgkin lymphoma, Yttrium-90 ibritumomab tiuxetan",
author = "Jo, {Jae Cheol} and Yoon, {Dok Hyun} and Shin Kim and Park, {Jung Sun} and Park, {Chan Sik} and Jooryung Huh and Lee, {Sang Wook} and Ryu, {Jin Sook} and Cheolwon Suh",
year = "2012",
month = "6",
day = "1",
doi = "10.5045/kjh.2012.47.2.119",
language = "English (US)",
volume = "47",
pages = "119--125",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma

AU - Jo, Jae Cheol

AU - Yoon, Dok Hyun

AU - Kim, Shin

AU - Park, Jung Sun

AU - Park, Chan Sik

AU - Huh, Jooryung

AU - Lee, Sang Wook

AU - Ryu, Jin Sook

AU - Suh, Cheolwon

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background Radioimmunotherapy agents have a highly significant role in autologous stem cell transplantation as they improve tolerability and increase the efficacy of the conditioning regimen. Methods We retrospectively analyzed the efficacy and toxicity of yttrium-90 ibritumomab tiuxetan (Zevalin) combined with intravenous busulfan, cyclophosphamide, and etoposide (Z-BuCyE) compared with those of BuCyE alone followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). The efficacy, toxicity, and engraftment characteristics were compared between 19 patients who received Z-BuCyE and 19 historical controls who received BuCyE. Results The 2 treatment groups shared similar baseline characteristics. The median time to platelet engraftment (>20×10 9/L) and neutrophil engraftment (>0.5×10 9/L) did not significantly differ between the Z-BuCyE group (12 days and 10 days, respectively) and the BuCyE group (12 days and 10 days, respectively). No significant differences were observed between the groups with respect to toxicities and treatment-related mortality. The median follow-up period was 30.4 months, and median event-free survival was generally better in the Z-BuCyE group (12.5 months) vs. the BuCyE group (6.2 months, P=0.236). No significant difference in overall survival between the groups was noted. Conclusion Adding ibritumomab tiuxetan to BuCyE high-dose chemotherapy may benefit patients with relapsed or refractory B-cell NHL with no risk of additional toxicity.

AB - Background Radioimmunotherapy agents have a highly significant role in autologous stem cell transplantation as they improve tolerability and increase the efficacy of the conditioning regimen. Methods We retrospectively analyzed the efficacy and toxicity of yttrium-90 ibritumomab tiuxetan (Zevalin) combined with intravenous busulfan, cyclophosphamide, and etoposide (Z-BuCyE) compared with those of BuCyE alone followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). The efficacy, toxicity, and engraftment characteristics were compared between 19 patients who received Z-BuCyE and 19 historical controls who received BuCyE. Results The 2 treatment groups shared similar baseline characteristics. The median time to platelet engraftment (>20×10 9/L) and neutrophil engraftment (>0.5×10 9/L) did not significantly differ between the Z-BuCyE group (12 days and 10 days, respectively) and the BuCyE group (12 days and 10 days, respectively). No significant differences were observed between the groups with respect to toxicities and treatment-related mortality. The median follow-up period was 30.4 months, and median event-free survival was generally better in the Z-BuCyE group (12.5 months) vs. the BuCyE group (6.2 months, P=0.236). No significant difference in overall survival between the groups was noted. Conclusion Adding ibritumomab tiuxetan to BuCyE high-dose chemotherapy may benefit patients with relapsed or refractory B-cell NHL with no risk of additional toxicity.

KW - Autologous stem cell transplantation

KW - Bucye

KW - Non-hodgkin lymphoma

KW - Yttrium-90 ibritumomab tiuxetan

UR - http://www.scopus.com/inward/record.url?scp=84866888387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866888387&partnerID=8YFLogxK

U2 - 10.5045/kjh.2012.47.2.119

DO - 10.5045/kjh.2012.47.2.119

M3 - Article

VL - 47

SP - 119

EP - 125

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 2

ER -